Genedata Joins Japanese Research Initiative For Metastatic Biomarkers

Main Category: Pharma Industry / Biotech Industry
Article Date: 14 Nov 2007 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Swiss-based research informatics provider Genedata announced its collaboration with Tokyo Medical University, AMR Inc., and Leica Microsystems in a proteomics research initiative aiming at the identification of metastatic biomarkers for the discovery and validation of new protein drug targets.

In the project, proteins extracted from lung and endocrine carcinoma FFPE tissue collections are analyzed using state-of-the-art MS-based proteomic methodologies. Formalin-fixed and paraffin-embedded (FFPE) tissue samples have been extensively collected and annotated in hospitals around the globe, representing an invaluable resource to study the progression of diseases in detail.

For the downstream molecular analysis, Genedata provides Expressionist, its modular enterprise system for biomarker discovery, along with comprehensive professional services. The high-throughput capabilities for quality assessment, pre-processing and integrated analysis make Genedata Expressionist a superior choice to handle the breadth and complexity of the mass-spectrometry based proteomics data, leading to the detection of molecular effects and interactions that would have otherwise gone unnoticed.

Professor Toshihide Nishimura, Department of Surgery, Tokyo Medical University, and Senior Advisor, Expression Pathology Inc. (USA), said: "Genedata`s support for our proteomics 'star alliance' is proving to be of outstanding value. Genedata Expressionist, as a capable high-throughput solution for proteomics analysis, is the key to unlocking a treasure chest of clinical samples for metastatic biomarker research that were intractable before."

"We are very pleased with our unique contribution," said Dr. Frank Staubli, Representative Director of Genedata KK in Japan. "MS-based retrospective proteomics represents an opportunity as well as a challenge for an integrated data processing and analysis system. Genedata Expressionist`s performance exceeds our expectations, and shows great potential for the scope of the collaboration."

About Genedata

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data; Genedata Screener® for screening analysis; and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin-off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Tokyo (Japan), Munich (Germany), Konstanz (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Taiwan and Singapore. For more information about Genedata, please visit http://www.genedata.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

http://www.genedata.com